Altered Viral Fitness and Drug Susceptibility in HIV-1 Carrying Mutations That Confer Resistance to Nonnucleoside Reverse Transcriptase and Integrase Strand Transfer Inhibitors

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

(2013) Michael E. Abram et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance

(2013) S. Alireza Rabi et al.   JOURNAL OF CLINICAL INVESTIGATION

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor

(2011) Olivia Goethals et al.   ANTIVIRAL RESEARCH

Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain

(2011) R. Di Santo   CURRENT MEDICINAL CHEMISTRY

Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine

(2011) Lotke Tambuyzer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

(2011) Laurence Rimsky et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

(2011) Jose-Luis Blanco et al.   JOURNAL OF INFECTIOUS DISEASES

Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations

(2011) H.-T. Xu et al.   JOURNAL OF VIROLOGY

Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1

(2011) Z. Hu et al.   JOURNAL OF VIROLOGY

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

(2011) Myron S. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug resistance in HIV-1

(2011) Daniel R Kuritzkes   Current Opinion in Virology

Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Assessing the Impact on Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitor Resistance

(2010) S. Gupta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates

(2010) L. Van Wesenbeeck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

(2010) Roy T. Steigbigel et al.   CLINICAL INFECTIOUS DISEASES

Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness

(2010) Zixin Hu et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

(2010) Hiroyu Hatano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Reduced Fitness in Cell Culture of HIV-1 with Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Mutations Correlates with Relative Levels of Reverse Transcriptase Content and RNase H Activity in Virions

(2010) J. Wang et al.   JOURNAL OF VIROLOGY

A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors

(2010) G. N. Nikolenko et al.   JOURNAL OF VIROLOGY

Retroviral intasome assembly and inhibition of DNA strand transfer

(2010) Stephen Hare et al.   NATURE

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance

(2010) S. Hare et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

(2009) Filippo Canducci et al.   AIDS

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identifying and Characterizing a Functional HIV-1 Reverse Transcriptase-binding Site on Integrase

(2009) Thomas A. Wilkinson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY

Selective-Advantage Profile of Human Immunodeficiency Virus Type 1 Integrase Mutants Explains In Vivo Evolution of Raltegravir Resistance Genotypes

(2009) R. Quercia et al.   JOURNAL OF VIROLOGY

Quantitative analysis of the interactions between HIV-1 integrase and retroviral reverse transcriptases

(2008) Alon Herschhorn et al.   BIOCHEMICAL JOURNAL

Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants†

(2008) Jessica Marinello et al.   BIOCHEMISTRY

Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition

(2008) Stefan G. Sarafianos et al.   JOURNAL OF MOLECULAR BIOLOGY

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

(2008) O. Goethals et al.   JOURNAL OF VIROLOGY

Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection

(2008) S. J. Little et al.   JOURNAL OF VIROLOGY

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase

(2008) Jingshan Ren et al.   VIRUS RESEARCH